Your browser is no longer supported. Please, upgrade your browser.
Settings
TRVN Trevena, Inc. daily Stock Chart
TRVN [NASD]
Trevena, Inc.
Index- P/E- EPS (ttm)-0.78 Insider Own5.12% Shs Outstand81.82M Perf Week-15.60%
Market Cap73.89M Forward P/E- EPS next Y-0.44 Insider Trans0.00% Shs Float71.96M Perf Month-44.25%
Income-49.00M PEG- EPS next Q-0.15 Inst Own50.10% Short Float10.01% Perf Quarter-36.85%
Sales2.50M P/S29.56 EPS this Y38.50% Inst Trans-0.03% Short Ratio1.93 Perf Half Y-48.39%
Book/sh0.56 P/B1.61 EPS next Y3.40% ROA-65.80% Target Price8.00 Perf Year-57.60%
Cash/sh0.78 P/C1.16 EPS next 5Y- ROE-125.40% 52W Range0.76 - 3.58 Perf YTD-43.56%
Dividend- P/FCF- EPS past 5Y-11.10% ROI- 52W High-75.85% Beta0.51
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin- 52W Low13.71% ATR0.33
Employees51 Current Ratio3.40 Sales Q/Q- Oper. Margin- RSI (14)35.49 Volatility21.52% 14.92%
OptionableYes Debt/Eq0.60 EPS Q/Q61.80% Profit Margin- Rel Volume0.77 Prev Close0.90
ShortableYes LT Debt/Eq0.28 EarningsNov 06 BMO Payout- Avg Volume3.74M Price0.86
Recom2.20 SMA20-55.68% SMA50-50.83% SMA200-49.91% Volume2,013,330 Change-4.31%
Oct-12-18Downgrade Needham Buy → Hold
Oct-10-18Downgrade Jefferies Buy → Hold
Nov-08-17Reiterated Needham Buy $9 → $7
Oct-16-17Downgrade Barclays Overweight → Equal Weight $15 → $2.50
Oct-12-17Reiterated H.C. Wainwright Buy $8 → $7
May-08-17Reiterated Needham Buy $11 → $9
Feb-23-17Reiterated H.C. Wainwright Buy $11 → $8
Feb-22-17Reiterated FBR & Co. Outperform $13 → $8
Feb-02-17Initiated Ladenburg Thalmann Buy $15
Jan-09-17Initiated H.C. Wainwright Buy $11
Jan-05-17Initiated Oppenheimer Outperform
May-17-16Reiterated Needham Buy $14 → $11
May-17-16Reiterated FBR Capital Outperform $13 → $16
Mar-29-16Initiated FBR Capital Outperform $16
Sep-01-15Reiterated Wedbush Outperform $15 → $20
Aug-03-15Initiated Brean Capital Buy $14
Jun-16-15Initiated ROTH Capital Buy $14.50
May-21-15Initiated Barclays Equal Weight $11
Feb-27-14Initiated Needham Buy $14
Feb-26-14Initiated Barclays Overweight $14
Oct-18-18 11:54AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRCO, MCHP, CPB and TRVN GlobeNewswire
10:20AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Trevena, Inc. (TRVN) & Lead Plaintiff Deadline: December 10, 2018 ACCESSWIRE
08:15AM  What's Next for Trevena? Pipeline and Analysts Review ACCESSWIRE
Oct-17-18 07:30PM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Trevena, Inc. - TRVN ACCESSWIRE -15.60%
05:48PM  SHAREHOLDER ALERT: TRCO MCHP ALNY MGTI CPB CHGG ADNT TRVN SFIX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
01:50PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:10PM  TREVENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Trevena, Inc. To Contact The Firm ACCESSWIRE
Oct-16-18 08:00PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Trevena, Inc. (TRVN) GlobeNewswire +26.18%
06:00PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
04:41PM  TREVENA, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Trevena Inc. GlobeNewswire
03:22PM  Block & Leviton Reminds Shareholders of Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm ACCESSWIRE
03:15PM  Kaskela Law LLC Files Shareholder Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Before Important Deadline TRVN GlobeNewswire
11:43AM  CLASS ACTION UPDATE for TRVN and GOOG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
09:42AM  Pomerantz Law Firm Announces the Filing of a Class Action against Trevena, Inc. and Certain Officers  TRVN GlobeNewswire
Oct-15-18 03:34PM  IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
03:01PM  CLASS ACTION UPDATE for TRVN and SFIX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
02:50PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Trevena, Inc. To Contact The Firm ACCESSWIRE
01:22PM  Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Trevena, Inc. Investors (TRVN) Business Wire
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Trevena, Inc. (TRVN) & Lead Plaintiff Deadline: December 10, 2018 GlobeNewswire
Oct-14-18 10:00AM  SHAREHOLDER ALERT: PDD AMPE MCHP MGTI HAS ADNT TRVN HTHT SFIX GOOG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Oct-13-18 12:10AM  INVESTOR ALERT: Kaskela Law LLC Announces Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - TRVN ACCESSWIRE
Oct-12-18 06:03PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire -7.06%
04:46PM  Robbins Arroyo LLP: Trevena, Inc. (TRVN) Misled Shareholders According to a Class Action Business Wire
04:01PM  Trevena to Present Phase 3, Open-Label Safety Study of Oliceridine at the American Society of Anesthesiologists Annual Meeting GlobeNewswire
03:04PM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Trevena, Inc. (TRVN) & Lead Plaintiff Deadline: December 10, 2018 PR Newswire
01:06PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRVN and SFIX GlobeNewswire
10:05AM  Trevena Losses Alert: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Trevena, Inc. TRVN GlobeNewswire
08:45AM  Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm ACCESSWIRE
08:27AM  The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena Zacks
07:34AM  The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program Benzinga
07:29AM  FDA advisory committee recommends not approving Trevena pain drug American City Business Journals
Oct-11-18 06:22PM  Trevena Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Trevena, Inc. - TRVN PR Newswire
06:12PM  Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Trevena, Inc. (TRVN) and Encourages TRVN Investors to Contact the Firm GlobeNewswire
06:05PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Trevena, Inc. Investors (TRVN) Business Wire
05:45PM  TREVENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Trevena, Inc. To Contact The Firm PR Newswire
05:45PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Trevena, Inc. TRVN Business Wire
05:35PM  Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm ACCESSWIRE
05:04PM  Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome GlobeNewswire
04:31PM  Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm TRVN GlobeNewswire
04:28PM  Trevena's opioid painkiller fails to get FDA panel backing Reuters
03:48PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Trevena, Inc. Investors (TRVN) Business Wire
03:39PM  Trevena's opioid painkiller fails to get FDA panel nod Reuters
02:44PM  Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Are Encouraged to Contact The Firm PR Newswire
01:42PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Trevena, Inc. GlobeNewswire
12:42PM  Bragar Eagel & Squire, P.C. is Investigating Trevena, Inc. (TRVN) on Behalf of Stockholders and Encourages TRVN Investors to Contact the Firm GlobeNewswire
12:16PM  INVESTOR ALERT: Investigation of Trevena Announced by Holzer & Holzer, LLC Business Wire
10:30AM  Cannabis and Biotech Stocks That Have Run Parabolically ACCESSWIRE
07:00AM  Trevena Stock Trading Halted; FDA Advisory Committee to Review Oliceridine for the Treatment of Moderate to Severe Acute Pain GlobeNewswire
Oct-10-18 08:22PM  INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Trevena Inc. Business Wire -11.50%
05:45PM  Trevena (TRVN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws; Investors Who Suffered Losses Exceeding $50,000 Encouraged to Contact the Firm ACCESSWIRE
03:05PM  Trevena Losses Alert: Bernstein Liebhard LLP Announces Investigation of Trevena, Inc. - TRVN GlobeNewswire
01:47PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Trevena, Inc. GlobeNewswire
12:32PM  AcelRx Shares React Positively To FDA Committee Briefing On Painkiller Candidate Dsuvia Benzinga
11:02AM  Trevena Losses Alert: Bernstein Liebhard LLP Announces Investigation Of Trevena, Inc. - TRVN PR Newswire
08:45AM  Trevena (TRVN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws; Investors Who Suffered Losses Exceeding $30,000 Encouraged to Contact the Firm ACCESSWIRE
08:19AM  Trevenas stock slides after safety concerns raised about new drug candidate American City Business Journals
08:00AM  Todays Research Reports on Stocks to Watch: Trevena and vTv Therapeutics ACCESSWIRE
Oct-09-18 02:29PM  Trevena (TRVN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws PR Newswire -64.09%
09:16AM  FDA staff raises safety issues over Trevena opioid injection Reuters
08:28AM  FDA staff raises safety concerns over Trevena opioid drug Reuters
Oct-05-18 10:55AM  Major Action in Biotech and This is The Next Winner ACCESSWIRE
Oct-03-18 08:00AM  Today's Research Reports on Trending Tickers: Paratek Pharmaceuticals and Trevena ACCESSWIRE +30.45%
Oct-01-18 11:27AM  New CEO takes over at Trevena American City Business Journals +10.85%
07:00AM  Trevena announces completion of leadership transition and appointment of new director GlobeNewswire
Sep-28-18 10:06AM  3 Biotech Stocks With Rising Estimates in the Past Month Zacks -5.78%
Sep-25-18 08:55AM  Implied Volatility Surging for Trevena (TRVN) Stock Options Zacks +8.72%
Sep-18-18 08:36PM  Analysts Bet Trevenas (TRVN) Pain Management Drug Will Get FDA Approval SmarterAnalyst
Sep-10-18 04:01PM  Trevena to Present Oliceridine, a Next Generation IV Opioid for the Management of Moderate to Severe Acute Pain, at FDA Advisory Committee Meeting on October 11, 2018 GlobeNewswire
Aug-30-18 04:30PM  Trevena to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire +8.92%
Aug-02-18 10:54AM  Trevena: 2Q Earnings Snapshot Associated Press
07:00AM  Trevena Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-24-18 12:00PM  Trevena (TRVN): Key Catalysts Coming Into View Investopedia
Jul-10-18 07:35AM  Complimentary Technical Snapshots on Trevena and Three More Biotech Stocks ACCESSWIRE
Jun-28-18 04:01PM  Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine GlobeNewswire
Jun-11-18 04:01PM  Trevena Expands Commercial and Medical Affairs Leadership Teams with Key Hires GlobeNewswire
Jun-08-18 07:00AM  TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE
Jun-05-18 09:37AM  Are New Drug Approvals Right Around the Corner for Trevena (TRVN) and Array Biopharma (ARRY)? SmarterAnalyst
Jun-02-18 12:02PM  Best High Growth NasdaqGS Stocks This Week Simply Wall St.
May-30-18 04:01PM  Trevena to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-24-18 07:20AM  Blog Exposure - Trevena Showcases Data from ATHENA Phase-3 Study at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting ACCESSWIRE
May-22-18 07:00AM  Trevena announces presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting GlobeNewswire
May-21-18 05:13PM  Trevena Appoints Mark A. Demitrack, M.D., as Chief Medical Officer GlobeNewswire
May-18-18 11:49AM  Edited Transcript of TRVN earnings conference call or presentation 3-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-08-18 04:01PM  Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -5.66%
May-04-18 12:28PM  Trevena signs second international product licensing deal, this time for China American City Business Journals +5.66%
May-03-18 10:11AM  Trevena: 1Q Earnings Snapshot Associated Press
07:00AM  Trevena Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 04:01PM  Trevena to Present at the Deutsche Bank 43rd Annual Healthcare Conference GlobeNewswire +14.36%
May-01-18 04:01PM  Trevena Inc. and Jiangsu Nhwa Pharmaceutical Co. Ltd Announce License Agreement for Oliceridine in China GlobeNewswire
Apr-27-18 01:09PM  $3M deal: Trevena signs licensing agreement with South Korean biopharm firm American City Business Journals +7.51%
08:00AM  Trevena and Pharmbio Korea Announce License and Commercialization Agreement for Oliceridine in South Korea GlobeNewswire
Apr-26-18 04:01PM  Trevena to Report First Quarter 2018 Financial Results on May 3, 2018 GlobeNewswire
08:20AM  New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals, and Trevena Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Apr-05-18 04:48PM  Founding CEO of Trevena biopharm firm to retire American City Business Journals
04:05PM  Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L. Bourdow to President and Chief Executive Officer GlobeNewswire
Mar-20-18 04:01PM  Trevena to Present at the Needham & Company 17th Annual Healthcare Conference GlobeNewswire
Mar-14-18 04:01PM  Trevena to Present at the Oppenheimer & Company 28th Annual Healthcare Conference GlobeNewswire
Mar-08-18 12:16PM  Edited Transcript of TRVN earnings conference call or presentation 7-Mar-18 1:00pm GMT Thomson Reuters StreetEvents +9.57%
Mar-07-18 04:01PM  Trevena to Present at the Cowen and Company 38th Annual Healthcare Conference GlobeNewswire -6.93%
10:01AM  3 Stocks Move Wednesday GuruFocus.com
Trevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Habib YacoubSVP, Bus Dev & Corp PlanningMar 22Sale1.765,0008,8000Mar 23 05:16 PM